**Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**
Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_ [FDA label].
**Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome**
Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions [FDA label].
**Pantoprazole delayed-release oral suspension**:
**Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)**
Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined [F3202].
**Maintenance of healing of erosive esophagitis**
Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD [F3202].
**Pathological hypersecretory conditions including Zollinger-Ellison syndrome**
Indicated for the long-term treatment of the above conditions [F3202].|
|DB00338||Omeprazole||Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults|
|DB00448||Lansoprazole||Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]|
|DB00736||Esomeprazole||Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome. |
|DB01129||Rabeprazole||For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.|
|DB05351||Dexlansoprazole||Dexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). |
|DB01377||Magnesium oxide||Indicated for over-the-counter use as a supplement for cardiovascular and neuromuscular health, and as an antacid for relief of acid indigestion and upset stomach.|
|DB06723||Aluminum hydroxide||For relief of heartburn and acid indigestion. |
|DB06724||Calcium Carbonate||For relief of heartburn and acid indigestion. May also be used as a nutritional supplement or to treat hypocalcemia. |
|DB09104||Magnesium hydroxide||Magnesium hydroxide can be used as an antacid or a laxative depending on the administered dose.
As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion.
As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.
|DB09281||Magnesium trisilicate||For the treatment of peptic ulcers.
Relieving indigestion and heartburn.|
|DB13209||Bismuth subnitrate||Indicated for over-the-counter use as an antacid. |
|DB13249||Magnesium silicate||Magnesium silicate is used to absorb moisture, prevent caking, and to improve the feel of a product. In the pharmaceutical companies, it is used as a dietary supplement, as part of the formulation ingredients in drug production, in antacid and antiulcer preparations, as a component of antiepileptic drugs, in antifungal topical agents and in the treatment of acne and as a facial moisturizer.[L2603]
When complexed with arginine, magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammals.[T186]|
|DB13280||Aluminium acetoacetate||Not Available|
|DB13486||Magnesium peroxide||Not Available|
|DB13595||Almasilate||Almasilate is indicated for use as an antacid for the neutralization of excess stomach acid [F25]. It is subsequently also used for the symptomatic treatment of diseases where it is necessary to neutralize acid in the stomach, for example, for treating stomach and duodenal ulcers or heartburn and stomach conditions caused by excess stomach acid [F25].|
|DB13626||Aluminium glycinate||Not Available|
|DB13829||Calcium silicate||Not Available|
|DB01390||Sodium bicarbonate||Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.|
|DB09481||Magnesium carbonate||Used as an over the counter antacid [L593].|
|DB14517||Aluminium phosphate||Not Available|
|DB00863||Ranitidine||This drug is used alone or with concomitant antacids for the following conditions [FDA label]:
Treatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose)
**Pathological hypersecretion of gastric acid**
Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion
Short term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose)
Treatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing [FDA label]
|DB00927||Famotidine||For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).|
|DB00501||Cimetidine||For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.|
|DB00940||Methantheline||For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.|
|DB08805||Metiamide||Potential in the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.|
|DB00585||Nizatidine||For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.|
|DB08806||Roxatidine acetate||For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers|
|DB15246||Salvianolic acid A||Not Available|